China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
BURLINGTON, Mass., March 28, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at Needham & Company’s 16th Annual Healthcare Conference on Tuesday, April 4, 2017 at 3:40 p.m. EDT at the Westin Grand Central Hotel in New York.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
